Taken together, these data suggest that CXCL16 may be a novel biomarker involved in the onset and deterioration of renal injury in diabetic patients, and the increased serum CXCL16 levels may be related to the abnormality of cholesterol metabolism in DN subjects. The gene discussed is CXCL16; the disease is liver dysplastic nodule.